| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document Help

Title:Translational regulation in hepatocellular carcinogenesis
Authors:ID Bračič Tomažič, Suzana (Author)
ID Schatz, Christoph (Author)
ID Haybaeck, Johannes (Author)
Files:.pdf Tomazic-2021-Translational_Regulation_in_Hepat.pdf (4,21 MB)
MD5: E55BEBA045618C20F661AE541769F393
 
URL https://doi.org/10.2147/DDDT.S255582
 
Language:English
Work type:Scientific work
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Abstract:The mortality of hepatocellular carcinoma (HCC) is distributed unevenly worldwide. One of the major causes is hepatitis B or hepatitis C virus infection and the development and progression of liver cirrhosis. The carcinogenesis of HCC is among others regulated via the mTOR (mechanistic target of rapamycin) signaling pathway and represents a possible method of targeted treatment. The aim of our article was to address the most recent clinical advances and findings of basic studies on the mTOR signaling pathway and the involved factors. Risk factors play a key role in dysregulation of the signaling pathway, where both mTORCs are upregulated and protein synthesis is altered. eIFs and, to a lesser extent, eEFs play an essential role in this process. Whether the factor will be upregulated or downregulated, among others, depends on hepatitis B/C virus infection. The amount of a particular factor in a patient sample lets us know whether HCC recurrence will occur, what is the likelihood of chemoresistance, and what outcome is predicted for patients with an increased value. Our analysis shows that in addition to mTOR, eIF3, eIF4, and eIF5 play an important role, as they can serve as biomarkers for non- and virus-related HCC.
Keywords:mTOR, virus related HCC, non-virus related HCC, cancer, translation initiation, liver
Publication status:Published
Publication version:Version of Record
Submitted for review:03.05.2021
Article acceptance date:04.10.2021
Publication date:14.10.2021
Publisher:Dovepress
Year of publishing:2021
Number of pages:Str. 4359-4369
Numbering:Letn. 15
PID:20.500.12556/DKUM-91070 New window
UDC:616.36-006
ISSN on article:1177-8881
COBISS.SI-ID:83680515 New window
DOI:10.2147/DDDT.S255582 New window
Publication date in DKUM:18.10.2024
Views:146
Downloads:11
Metadata:XML DC-XML DC-RDF
Categories:Misc.
:
Copy citation
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share



Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Drug design, development and therapy
Shortened title:Drug des. dev. ther.
Publisher:Dove Medical Press
ISSN:1177-8881
COBISS.SI-ID:523059481 New window

Licences

License:CC BY-NC 3.0, Creative Commons Attribution-NonCommercial 3.0 Unported
Link:http://creativecommons.org/licenses/by-nc/3.0/
Description:You are free to reproduce and redistribute the material in any medium or format. You are free to remix, transform, and build upon the material. You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Licensing start date:14.10.2021

Secondary language

Language:Slovenian
Keywords:Hepatocelularni karcinom, rak, povezava z virusom, začetek prevajanja, jetra


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica